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Abstract
Background: Carcinoma and adenoma of the duodenum, including the papilla of Vater, are problematic diseases
in patients with familial adenomatous polyposis (FAP).
Case presentation: A 36-year-old man underwent a periodic medical examination for early colon cancer
originating from FAP for which laparoscopic-assisted subtotal colectomy with a J-shaped ileal pouch-rectal
anastomosis was performed 3 years earlier. A tumor was detected at the papilla of Vater along with elevation of
total bilirubin and hepatobiliary enzymes. Although cytology did not determine the tumor to be an
adenocarcinoma, we suspected adenocarcinoma due to its hypervascularity shown by contrast-enhanced
computed tomography. Pylorus-preserving pancreaticoduodenectomy with modified Imanaga reconstruction and
regional lymph node dissection (D2) was performed. The pathological study showed that the tumor was a papillary
and moderately differentiated tubular adenocarcinoma. The patient is currently in good health without recurrence,
weight loss, or severe diarrhea at 12 months after surgery.
Conclusions: Awareness of biliary-pancreatic symptoms and periodic gastroduodenoscopy might contribute both
to the early detection of duodenal or periampullary polyps and cancer and to the radical treatment of FAP.
Modified Imanaga reconstruction has the potential to become one of the more effective procedures for providing
good quality of life to FAP patients with duodenal or periampullary cancer.
Keywords: Familial adenomatous polyposis, Duodenal and ampullary cancer, Modified Imanaga reconstruction,
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Background
Carcinoma and adenoma of the duodenum, including the
papilla of Vater, are problematic diseases in patients with
familial adenomatous polyposis (FAP), especially as duo-
denal polyps were detected in 65 % of FAP patients with a
median age of 38 years [1]. Duodenal adenoma changes to
adenocarcinoma via the adenoma-carcinoma sequence,
but the incidence rate is only approximately 5 % of all
polyps [2–4]. The establishment of endoscopic manage-
ment and treatment of patients with FAP based on the
Spigelman scoring system contributes to surveillance
alone or to endoscopic mini-invasive treatment of stage
0–III patients, although even now, almost all patients with
stage IV disease and cancer require short-term surveil-
lance or endoscopic treatment or surgery [5].
For stage IV patients, several treatments, including
endoscopic mucosal resection, ampullectomy, and
pancreas-preserving duodenectomy (PpD)/pylorus-pre-
serving pancreaticoduodenectomy (PpPD), have been
discussed and recommended [5–7]; however, the pa-
tients managed with endoscopic resection of adenomas
continue to be at substantial risk of developing recurrent
adenomas [7]. For patients with duodenal or ampullary
cancer, PpD/PpPD is selected in most cases [6, 8, 9].* Correspondence: b-joel555shuji-k@violin.ocn.ne.jp
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We report a case of the onset of cancer of the papilla
of Vater in a young man after subtotal colectomy for
FAP. The available diagnostic and therapeutic strategies
for surgical treatment are also discussed in light of the
experience with the present case and in reference to pre-
viously reported cases.
Case presentation
A 36-year-old man underwent a periodic medical exam-
ination for early colon cancer originating from classical
FAP (adenomatous polyposis coli (APC) gene in 5q21
analysis, codon 1–1800: exon 15, codon 795, 1 bp dele-
tion of C: CTC→CT) for which laparoscopic-assisted
subtotal colectomy with a J-shaped ileal pouch-rectal
anastomosis was performed 3 years earlier. His mother
also has FAP and the same gene mutation as with his
subtype and gene and underwent the same operation
13 years earlier and resection of an intra-abdominal des-
moid tumor 10 years earlier (Fig. 1).
Enhanced computed tomography (CT) showed a
hypervascular tumor, 10 mm in diameter, at the papilla
of Vater and dilation of the common bile duct (CBD)
and the intrahepatic bile duct (Fig. 2a–c), and therefore,
detailed studies were performed. Results of laboratory
blood tests showed high values of aspartate aminotrans-
ferase (169 IU/l), alanine aminotransferase (164 IU/l),
alkaline phosphatase (755 IU/l), γ-glutamyltransferase
(452 IU/l), total bilirubin (1.96 mg/dl), and pancreatic
amylase (382 IU/l).
Magnetic resonance imaging (MRI) and magnetic res-
onance cholangiopancreatography (MRCP) showed the
tumor as a defect present from the papilla of Vater to
the lower CBD (Fig. 3a, b). Gastroduodenoscopy showed
a large number of gastric and duodenal polyps and a
duodenal ulcer nearby the papilla of Vater, which were
suspected to be tumor invasion (Fig. 4a, b). Moreover,
endoscopic retrograde cholangiopancreatography de-
tected the same findings as those of the MRI and MRCP,
and intraductal ultrasonography (IDUS) detected a tor-
ose lesion at the lower CBD (Fig. 5a, b). Although a
biopsy of the lesion did not reveal any apparent cancer
cells, we suspected the tumor to be a malignant tumor
of the papilla of Vater because of the hypervascularity
shown by CT. No regional lymph node swelling, metas-
tases, or direct invasion to adjacent organs was detected
on the chest and abdominal CT images, and there were
no other FAP-related findings in other organs. PpPD
with modified Imanaga reconstruction, which consists of
end-to-side duodenojejunostomy, end-to-side pancreato-
jejunostomy and choledochojejunostomy, and regional
lymph node dissection (D2), were performed.
The specimen obtained showed a circular infiltrating
papillary tumor 10 mm in diameter with a shallow ulcer
at the papilla of Vater and a large number of polyps in
the duodenal second portion (Fig. 6a). The pathological
study indicated that the tumor was a papillary and mod-
erately differentiated tubular adenocarcinoma (pStage: II,
invasion level: duodenum alone (T2), lymphatic duct in-
vasion: mild, vessel invasion: mild, neural invasion: not
detected) (Fig. 6b). Although a large number of aden-
omas were found in the portion of the duodenum, re-
gional lymph node, liver, and distant metastasis and
peritoneal dissemination were not noted (pN0, H0, M0,
P0). The patient is currently in good health without re-
currence, weight loss, or severe diarrhea at 12 months
after surgery.
Discussion
Cancer of the duodenum and the papilla of Vater affects
the prognosis of patients with FAP. Many of these pa-
tients have adenomatous polyps in the second and third
portions of the duodenum, and although the polyps re-
main adenomatous in many cases, 5 % of the polyps
change from adenoma to carcinoma via the adenoma-
carcinoma sequence [2, 4, 8, 10]. Interestingly, Kadmon
et al. reported that no clear association between the
number of colon polyps and the number of upper
gastrointestinal polyps has been identified [11], whereas
the presence of colorectal cancer is related to the in-
crease in duodenal or periampullary cancer in patients
with FAP [12]. Therefore, patients with FAP independ-
ently need to undergo periodic gastroduodenoscopy and
side-viewing endoscopy such as colonoscopy.
Polyps in the periampullary area can cause obstruction
of the biliary and pancreatic ducts, resulting in elevation
of bilirubin and hepatobiliary pancreatic enzymes, jaun-
dice, or pancreatitis as in our case [10], which suggests
that awareness of biliary-pancreatic symptoms yields an
Fig. 1 The patient’s family tree
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Fig. 2 Enhanced CT image showed a hypervascular tumor, 10 mm in diameter, at the papilla of Vater (arrow) (a) and dilation of the common
and intrahepatic bile ducts (arrow) (b, c)
Fig. 3 An MRI and MRCP showed the tumor as a defect from the papilla of Vater to the lower CBD (arrow) (a, b)
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opportunity to check for periampullary polyps in pa-
tients with FAP along with periodic gastroduodenoscopy.
However, this does not diminish the primary importance
of periodic medical surveillance for FAP patients.
According to the Spigelman scoring system, several
treatments, among which are endoscopic mucosal resec-
tion, endoscopic ampullectomy, and prophylactic PpD/
PpPD, are applicable to stage IV patients; however more
invasive treatments, such as surgical procedures including
PpPD, are applicable to cancer patients [5–8]. The risk of
recurrence of both stage IV disease and cancer remains
substantial. Especially, less invasive treatments result in
high rates of recurrence of adenomas/cancer: rates follow-
ing ampullectomy for early ampullary cancer range from
10 to 12.8 %, and that following PpD for duodenal aden-
omas/cancer is 50 % [7, 12–14]. Therefore, individual
patient characteristics need to be carefully considered
when adopting a less invasive treatment.
For duodenal or periampullary cancer, there would be
no objection to performing pancreaticoduodenectomy
(PD), and thus in many cases, PpPD is performed. Several
authors have reported no difference in perioperative mor-
bidity, long-term survival, and other factors between PD
and PpPD. However, except for the incidence of delayed
gastric emptying, PpPD is better than PD in terms of op-
erating time, blood loss, nutritional status, and capacity to
work at 6 months after surgery [15–19]. The Whipple or
child reconstruction procedure is usually performed to
avoid complications of pancreatic fistula (PF), abdominal
abscess, or hemorrhage. However, these procedures do
not create a physiological route; the modified Imanaga re-
construction is a physiological procedure that offers good
Fig. 4 Gastroduodenoscopy revealed a duodenal ulcer nearby the papilla of Vater (arrow), which was suspected as the site of tumor invasion (a),
and a large number of duodenal polyps (dotted arrows) (b)
Fig. 5 Endoscopic retrograde cholangiopancreatography detected findings similar to those of the MRI and MRCP (arrow) (a), and IDUS detected
a torose lesion (dotted arrow) at the lower CBD (b)
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long-term nutritional status and allows easier postopera-
tive observation and treatment of the pancreatic/biliary
duct [20]. The weak point of the modified Imanaga recon-
struction is that it occasionally intensifies the severity of
PF or cholangitis more than that by the Whipple or child
procedure, and it delays ingestion when PF occurs. Never-
theless, there are at least two benefits of the modified Ima-
naga reconstruction in FAP: ease of endoscopic intestinal
observation/treatment and maintenance of nutritional sta-
tus after subtotal colectomy for colorectal lesions of FAP.
Therefore, we selected the modified Imanaga procedure
for our patient. However, after performing the PpPD in
our patient, we experienced a patient with duodenal can-
cer arising from the remaining duodenum after PpPD for
ampullary cancer in FAP [21], suggesting that resection of
the pylorus and the duodenal bulb with pylorus-resecting
PD (PrPD) can remove all of the duodenum and contrib-
utes to the prevention of any remaining duodenal cancer
in patients with FAP. Moreover, long-term outcomes of
PrPD are similar to those of PpPD, and PrPD reduces the
incidence of delayed gastric emptying compared with
PpPD [22–24]. Thus, PrPD with the modified Imanaga
procedure might be a better option in patients with FAP.
Further evaluation with high-quality prospective studies is
necessary.
Conclusions
In the future, expanded oncological, pathological, and sur-
gical knowledge of duodenal or periampullary polyps and
cancer associated with FAP might bring many FAP patients
more relevant treatment than they receive at present. Al-
though more study is necessary, PrPD with the modified
Imanaga reconstruction has the potential to become one of
the more effective procedures for the treatment of FAP.
Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal on request.
Abbreviations
CBD: common bile duct; CT: computed tomography; FAP: familial
adenomatous polyposis; IDUS: intraductal ultrasonography; MRCP: magnetic
resonance cholangiopancreatography; MRI: magnetic resonance imaging;
PD: pancreaticoduodenectomy; PF: pancreatic fistula; PpD: pancreas-




The authors declare that they have no competing interests.
Authors’ contributions
Shuji K wrote the manuscript. Shuji K, MK, and TN performed the surgery.
Shuji K, KM, CS, MK, YS, MF, YA, MT, Shigeru K, CT, YN, and NN acquired the
data. Shuji K interpreted the data and drafted the manuscript. Shuji K, MK,
TN, and KK performed critical revision of the manuscript. Rise Japan (rise-
japan.rulez.jp) reviewed the English language of the original manuscript.
All authors read and approved the final manuscript.
Received: 22 August 2015 Accepted: 17 February 2016
References
1. Bülow S, Björk J, Christensen IJ, Fausa O, Järvinen H, Moesgaard F, et al.
Duodenal adenomatosis in familial adenomatous polyposis. Gut. 2004;53:
381–6.
2. Nugent KP, Spigelman AD, Phillips RK. Life expectancy after colectomy and
ileorectal anastomosis for familial adenomatous polyposis. Dis Colon
Rectum. 1993;36:1059–62.
3. Nakatsubo N, Kashiwagi H, Okumura M, Kamoshida T, Takahashi A, Spigelman
AD. Malignant change in a duodenal adenoma in familial adenomatous
polyposis: report of a case. Am J Gastroenterol. 1998;93:1566–8.
4. Spigelman AD, Talbot IC, Penna C, Nugent KP, Phillips RK, Costello C, et al.
Evidence for adenoma-carcinoma sequence in the duodenum of patients
with familial adenomatous polyposis. The Leeds Castle Polyposis Group
(Upper Gastrointestinal Committee). J Clin Pathol. 1994;47:709–10.
Fig. 6 The resected specimen showed a 10-mm circular infiltrating papillary tumor (arrow) with a shallow ulcer (dotted arrow) at the papilla of
Vater and polyps (arrowheads) in the duodenal second portion (a). The pathological study showed that the tumor was a papillary and moderately
differentiated tubular adenocarcinoma (b)
Komori et al. World Journal of Surgical Oncology  (2016) 14:47 Page 5 of 6
5. Groves CJ, Saunders BP, Spigelman AD, Phillips RK. Duodenal cancer in
patients with familial adenomatous polyposis (FAP): results of a 10 year
prospective study. Gut. 2002;50:636–41.
6. Parc Y, Mabrut JY, Shields C, Mallorca Group. Surgical management of the
duodenal manifestations of familial adenomatous polyposis. Br J Surg. 2011;
98:480–4.
7. Johnson MD, Mackey R, Brown N, Church J, Burke C, Walsh RM. Outcome
based on management for duodenal adenomas: sporadic versus familial
disease. J Gastrointest Surg. 2010;14:229–35.
8. Skipworth JR, Morkane C, Raptis DA, Vyas S, Olde Damink SW, Imber CJ, et al.
Pancreaticoduodenectomy for advanced duodenal and ampullary
adenomatosis in familial adenomatous polyposis. HPB (Oxford). 2011;13:342–9.
9. de Castro SM, van Eijck CH, Rutten JP, Dejong CH, van Goor H, Busch OR, et
al. Pancreas-preserving total duodenectomy versus standard
pancreatoduodenectomy for patients with familial adenomatous polyposis
and polyps in the duodenum. Br J Surg. 2008;95:1380–6.
10. Wallace MH, Phillips RK. Upper gastrointestinal disease in patients with
familial adenomatous polyposis. Br J Surg. 1998;85:742–50.
11. Kadmon M, Tandara A, Herfarth C. Duodenal adenomatosis in familial
adenomatous polyposis coli. A review of the literature and results from the
Heidelberg Polyposis Register. Int J Colorectal Dis. 2001;16:63–75.
12. van Heumen BW, Nieuwenhuis MH, van Goor H, Mathus-Vliegen LE, Dekker
E, Gouma DJ, et al. Surgical management for advanced duodenal
adenomatosis and duodenal cancer in Dutch patients with familial
adenomatous polyposis: a nationwide retrospective cohort study. Surgery.
2012;151:681–90.
13. Yoon YS, Kim SW, Park SJ, Lee HS, Jang JY, Choi MG, et al. Clinicopathologic
analysis of early ampullary cancers with a focus on the feasibility of
ampullectomy. Ann Surg. 2005;242:92–100.
14. Kawabata Y, Ishikawa N, Moriyama I, Tajima Y. What is an adequate surgical
management for pTis and pT1 early ampullary carcinoma?
Hepatogastroenterology. 2014;61:12–7.
15. Seiler CA, Wagner M, Bachmann T, Redaelli CA, Schmied B, Uhl W, et al.
Randomized clinical trial of pylorus-preserving duodenopancreatectomy versus
classical Whipple resection-long term results. Br J Surg. 2005;92:547–56.
16. Karanicolas PJ, Davies E, Kunz R, Briel M, Koka HP, Payne DM, et al. The
pylorus: take it or leave it? Systematic review and meta-analysis of pylorus-
preserving versus standard whipple pancreaticoduodenectomy for
pancreatic or periampullary cancer. Ann Surg Oncol. 2007;14:1825–34.
17. Tran KT, Smeenk HG, van Eijck CH, Kazemier G, Hop WC, Greve JW, et al.
Pylorus preserving pancreaticoduodenectomy versus standard Whipple
procedure: a prospective, randomized, multicenter analysis of 170 patients
with pancreatic and periampullary tumors. Ann Surg. 2004;240:738–45.
18. Ogata Y, Hishinuma S. The impact of pylorus-preserving
pancreatoduodenectomy on surgical treatment for cancer of the pancreatic
head. J Hepatobiliary Pancreat Surg. 2002;9:223–32.
19. Niedergethmann M, Shang E, Farag Soliman M, Saar J, Berisha S, Willeke F,
et al. Early and enduring nutritional and functional results of pylorus
preservation vs classic Whipple procedure for pancreatic cancer.
Langenbecks Arch Surg. 2006;391:195–202.
20. Ohtsuka T, Tanaka M, Miyazaki K. Gastrointestinal function and quality of life
after pylorus-preserving pancreatoduodenectomy. J Hepatobiliary Pancreat
Surg. 2006;13:218–24.
21. Murakami Y, Uemura K, Sasaki M, Morifuji M, Hayashidani Y, Sudo T, et al.
Duodenal cancer arising from the remaining duodenum after pylorus-
preserving pancreatoduodenectomy for ampullary cancer in familial
adenomatous polyposis. J Gastrointest Surg. 2005;9:389–92.
22. Kawai M, Tani M, Hirono S, Miyazawa M, Shimizu A, Uchiyama K, et al.
Pylorus ring resection reduces delayed gastric emptying in patients
undergoing pancreatoduodenectomy: a prospective, randomized,
controlled trial of pylorus-resecting versus pylorus-preserving
pancreatoduodenectomy. Ann Surg. 2011;253:495–501.
23. Kawai M, Tani M, Hirono S, Okada K, Miyazawa M, Yamaue H. Pylorus-
resecting pancreaticoduodenectomy offers long-term outcomes similar to
those of pylorus-preserving pancreaticoduodenectomy: results of a
prospective study. World J Surg. 2014;38:1476–83.
24. Yang C, Wu HS, Chen XL, Wang CY, Gou SM, Xiao J, et al. Pylorus-preserving
versus pylorus-resecting pancreaticoduodenectomy for periampullary and
pancreatic carcinoma: a meta-analysis. PLoS One. 2014;9:e90316.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Komori et al. World Journal of Surgical Oncology  (2016) 14:47 Page 6 of 6
